126 related articles for article (PubMed ID: 17465640)
1. Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.
Dartois C; Freyer G; Michallet M; Hénin E; You B; Darlavoix I; Vermot-Desroches C; Tranchand B; Girard P
Clin Pharmacokinet; 2007; 46(5):417-32. PubMed ID: 17465640
[TBL] [Abstract][Full Text] [Related]
2. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I; Valcárcel D; Martino R; Piñana JL; Novelli S; Esquirol A; Garrido A; Moreno ME; Granell M; Moreno C; Saavedra S; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2013 Mar; 19(3):435-9. PubMed ID: 23178634
[TBL] [Abstract][Full Text] [Related]
3. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.
Socié G; Vigouroux S; Yakoub-Agha I; Bay JO; Fürst S; Bilger K; Suarez F; Michallet M; Bron D; Gard P; Medeghri Z; Lehert P; Lai C; Corn T; Vernant JP
Blood; 2017 Feb; 129(5):643-649. PubMed ID: 27899357
[TBL] [Abstract][Full Text] [Related]
5. Inolimomab (OPi).
Winkler M
Curr Opin Investig Drugs; 2002 Oct; 3(10):1464-7. PubMed ID: 12431019
[TBL] [Abstract][Full Text] [Related]
6. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
[TBL] [Abstract][Full Text] [Related]
7. Inolimomab. Anti-CD25 monoclonal antibody B-B10, anti-interleukin-2 receptor monoclonal antibody B-B10, B-B10, BT 563, Leukotac.
Drugs R D; 1999 Jan; 1(1):81-4. PubMed ID: 10565995
[No Abstract] [Full Text] [Related]
8. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.
Cahn JY; Bordigoni P; Tiberghien P; Milpied N; Brion A; Widjenes J; Lioure B; Michel G; Burdach S; Kolb HJ
Transplantation; 1995 Nov; 60(9):939-42. PubMed ID: 7491697
[TBL] [Abstract][Full Text] [Related]
10. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.
Piñana JL; Valcárcel D; Martino R; Moreno ME; Sureda A; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1135-41. PubMed ID: 17085306
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.
Girerd S; Renaud M; Guilhot J; Giraud C; Larchee R; Jollet I; Guilhot F
Bone Marrow Transplant; 2013 Sep; 48(9):1243-8. PubMed ID: 23503532
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.
Martin PJ; Pei J; Gooley T; Anasetti C; Appelbaum FR; Deeg J; Hansen JA; Nash RA; Petersdorf EW; Storb R; Ghetie V; Schindler J; Vitetta ES
Biol Blood Marrow Transplant; 2004 Aug; 10(8):552-60. PubMed ID: 15282533
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
[TBL] [Abstract][Full Text] [Related]
17. [The role of CD25 antibody in unrelated hematopoietic stem cell transplantation].
Hu LD; Chen H; Jiang M; Li BT; Yu ZY; Li YH
Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):848-50. PubMed ID: 16316569
[TBL] [Abstract][Full Text] [Related]
18. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.
Couriel DR; Saliba R; Escalón MP; Hsu Y; Ghosh S; Ippoliti C; Hicks K; Donato M; Giralt S; Khouri IF; Hosing C; de Lima MJ; Andersson B; Neumann J; Champlin R
Br J Haematol; 2005 Aug; 130(3):409-17. PubMed ID: 16042691
[TBL] [Abstract][Full Text] [Related]
20. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]